Fosun Pharmaceutical announced that the registration application for furitinib succinate capsules submitted again by its holding subsidiary Fosun Wanbang Pharmaceutical Group Co., Ltd. was accepted by the State Drug Administration. The application for locally advanced or metastatic non-small cell lung cancer patients with ALK-positive indications was accepted by the State Drug Administration. The new drug is an innovative small molecule chemical drug. Phase II clinical studies for non-small cell lung cancer have been completed in China as another indication. As of November 2025, the total R&D investment for this new drug was approximately 480 million yuan. In 2024, the sales volume of ALK+'s main drug for non-small cell lung cancer in China was about 3.367 billion yuan.

Fosun Pharmaceutical announced that the registration application for furitinib succinate capsules submitted again by its holding subsidiary Fosun Wanbang Pharmaceutical Group Co., Ltd. was accepted by the State Drug Administration. The application for locally advanced or metastatic non-small cell lung cancer patients with ALK-positive indications was accepted by the State Drug Administration. The new drug is an innovative small molecule chemical drug. Phase II clinical studies for non-small cell lung cancer have been completed in China as another indication. As of November 2025, the total R&D investment for this new drug was approximately 480 million yuan. In 2024, the sales volume of ALK+'s main drug for non-small cell lung cancer in China was about 3.367 billion yuan.